☆ 4.5 Article

Regulatory decisions pertaining to aprotinin may be putting patients at risk

CANADIAN MEDICAL ASSOCIATION JOURNAL (2014)

Get Full Text
Add to Collection

Journal

CANADIAN MEDICAL ASSOCIATION JOURNAL
Volume 186, Issue 18, Pages 1379-1386

Publisher

CMA-CANADIAN MEDICAL ASSOC
DOI: 10.1503/cmaj.131582

Keywords

-

Categories

Medicine, General & Internal

Funding

  1. Bayer
  2. Cubist
  3. Medicines Company
  4. NovoNordisk
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Oxygen Biotherapeutics
  8. Hemocon
  9. Quark Pharmaceuticals
  10. Hospira
  11. Fresenius-Kabi

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.